Floatz logo

SL-28

Malignant Pancreatic Neoplasm

Second Life TherapeuticsUNKNOWNPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

314 Active assets in the Malignant Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

SL-28 is also rated in:

intestinal cancerActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
head and neck cancerActive
CC
Indicative · Phase 1/2
47 / 100
View asset →
non-small cell lung carcinomaActive
CC
Indicative · Phase 1/2
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →